<unk>  (marketed by ViiV Healthcare as the calcium salt under the trade names Lexiva in the U.S. and Telzir in Europe) is a drug for the treatment of HIV infections. It is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The US Food and Drug Administration (FDA) approved it on 20 October 2003, while the European Medicines Agency (EMA) approved it on 12 July 2004. The human body metabolizes<unk>  in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making<unk>  a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir. A head-to-head study with lopinavir showed the two drugs to have comparable potency, but patients on<unk>  tended to have a higher serum cholesterol.<unk> 's main advantage over lopinavir is that it is cheaper.
Fosamprenavir
Saquinavir
Coronavir
Entecavir
Indinavir
Abacavir
Amprenavir
Fostemsavir